Research programme: indomethacin/phosphatidylcholine - PLx Pharma/UTHealthAlternative Names: Phosphatidylcholine-enriched indomethacin
Latest Information Update: 30 Mar 2012
At a glance
- Originator PLx Pharma; University of Texas Health Science Center at Houston
- Class Nonsteroidal anti-inflammatories; Phospholipids
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Phase Unknown Congenital heart defects
Most Recent Events
- 30 Mar 2012 Investigation in Congenital heart disorders in USA (unspecified route)